Overview
- RadNet said CIMAR will be integrated into its DeepHealth unit to enhance AI-powered reporting, workflow and data connectivity.
- CIMAR’s vendor-neutral infrastructure supports more than 50% of NHS Trusts and about 80% of UK private hospital groups.
- The existing partnership underpins NHS England’s Lung Cancer Screening Program, linking DeepHealth’s AI at over 90% of screening sites.
- Program partners report that early-stage detection in the AI-enabled lung screening effort has reached 76%, compared with a historical 29%.
- RadNet posted Q3 revenue of $522.9 million and lifted its 2025 sales outlook to $1.985–$2.025 billion, while financial terms of the CIMAR deal were not disclosed.